TME Pharma N.V. (ALTME.PA)
EUR 0.06
(1.1%)
EUR 0.06
(1.1%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -5.07 Million EUR | 51.93% |
| 2022 | -11.63 Million EUR | 9.69% |
| 2021 | -12.88 Million EUR | -143.61% |
| 2020 | -5.28 Million EUR | -552.84% |
| 2019 | -810 Thousand EUR | 79.52% |
| 2018 | -3.95 Million EUR | -7.44% |
| 2017 | -3.68 Million EUR | 54.43% |
| 2016 | -8.43 Million EUR | 42.71% |
| 2015 | -14.61 Million EUR | -9.45% |
| 2014 | -12.88 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.66 Million EUR | 0.0% |
| 2023 Q4 | -1.41 Million EUR | -0.74% |
| 2023 FY | - EUR | 52.75% |
| 2023 Q1 | -1.35 Million EUR | 68.09% |
| 2023 Q2 | -1.35 Million EUR | 0.0% |
| 2023 Q3 | -1.4 Million EUR | -3.61% |
| 2022 Q3 | -2.13 Million EUR | 72.27% |
| 2022 Q2 | -7.69 Million EUR | -100.0% |
| 2022 FY | - EUR | 9.69% |
| 2022 Q1 | -3.84 Million EUR | 48.47% |
| 2022 Q4 | -4.24 Million EUR | -98.64% |
| 2021 Q3 | -3.7 Million EUR | 38.22% |
| 2021 Q2 | -5.99 Million EUR | -100.0% |
| 2021 FY | - EUR | -143.61% |
| 2021 Q1 | -2.99 Million EUR | 23.79% |
| 2021 Q4 | -7.46 Million EUR | -101.56% |
| 2020 Q3 | -1.95 Million EUR | -2.93% |
| 2020 FY | - EUR | -552.84% |
| 2020 Q4 | -3.93 Million EUR | -101.21% |
| 2020 Q1 | -933.5 Thousand EUR | 50.58% |
| 2020 Q2 | -1.9 Million EUR | -103.54% |
| 2019 FY | - EUR | 79.52% |
| 2019 Q4 | -1.88 Million EUR | -86.02% |
| 2019 Q3 | -1.01 Million EUR | 55.6% |
| 2019 Q2 | -2.28 Million EUR | -127.22% |
| 2019 Q1 | -1 Million EUR | 2.09% |
| 2018 Q3 | -1.02 Million EUR | 18.96% |
| 2018 Q4 | -1.02 Million EUR | 0.0% |
| 2018 Q2 | -1.26 Million EUR | 0.0% |
| 2018 Q1 | -1.26 Million EUR | -13.06% |
| 2018 FY | - EUR | -7.44% |
| 2017 Q3 | -1.12 Million EUR | 8.97% |
| 2017 Q1 | -1.23 Million EUR | 21.73% |
| 2017 Q2 | -1.23 Million EUR | 0.0% |
| 2017 Q4 | -1.12 Million EUR | 0.0% |
| 2017 FY | - EUR | 54.43% |
| 2016 Q1 | -2.46 Million EUR | 28.65% |
| 2016 FY | - EUR | 42.71% |
| 2016 Q4 | -1.57 Million EUR | -1.93% |
| 2016 Q2 | -2.46 Million EUR | 0.0% |
| 2016 Q3 | -1.54 Million EUR | 37.3% |
| 2015 Q1 | -3.6 Million EUR | 0.0% |
| 2015 Q3 | -3.45 Million EUR | 4.08% |
| 2015 FY | - EUR | -9.45% |
| 2015 Q4 | -3.45 Million EUR | 0.0% |
| 2015 Q2 | -3.6 Million EUR | 0.0% |
| 2014 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -54.164% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 96.192% |
| Adocia SA | -22.73 Million EUR | 77.688% |
| Aelis Farma SA | -6.34 Million EUR | 20.088% |
| Biophytis S.A. | -13.8 Million EUR | 63.257% |
| Advicenne S.A. | -6.24 Million EUR | 18.77% |
| genOway Société anonyme | 6.35 Million EUR | 179.865% |
| IntegraGen SA | -52.5 Thousand EUR | -9560.4% |
| Medesis Pharma S.A. | -3.84 Million EUR | -31.916% |
| Neovacs S.A. | -8.44 Million EUR | 39.973% |
| NFL Biosciences SA | -4.04 Million EUR | -25.256% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 7092.968% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -76.511% |
| Sensorion SA | -22.31 Million EUR | 77.27% |
| Theranexus Société Anonyme | -7.38 Million EUR | 31.341% |
| Valbiotis SA | -6.95 Million EUR | 27.074% |
| TheraVet SA | -517.33 Thousand EUR | -880.407% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 73.187% |
| argenx SE | -199.5 Million EUR | 97.458% |
| BioSenic S.A. | -6.79 Million EUR | 25.368% |
| Celyad Oncology SA | -7.76 Million EUR | 34.664% |
| DBV Technologies S.A. | -79.53 Million EUR | 93.623% |
| Galapagos NV | 51.03 Million EUR | 109.938% |
| Genfit S.A. | -28.05 Million EUR | 81.919% |
| GeNeuro SA | -14.31 Million EUR | 64.575% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 66.142% |
| Innate Pharma S.A. | -7.57 Million EUR | 33.069% |
| Inventiva S.A. | -101.84 Million EUR | 95.02% |
| MaaT Pharma SA | -19.74 Million EUR | 74.306% |
| MedinCell S.A. | -20.04 Million EUR | 74.698% |
| Nanobiotix S.A. | -34.01 Million EUR | 85.091% |
| Onward Medical N.V. | -35.23 Million EUR | 85.605% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -14.405% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 78.2% |
| Oxurion NV | -16.72 Million EUR | 69.681% |
| Pharming Group N.V. | 4.98 Million EUR | 201.828% |
| Poxel S.A. | -12.17 Million EUR | 58.355% |
| GenSight Biologics S.A. | -21.73 Million EUR | 76.659% |
| Transgene SA | -27.02 Million EUR | 81.231% |
| Financière de Tubize SA | 184.57 Thousand EUR | 2847.994% |
| UCB SA | 1.26 Billion EUR | 100.4% |
| Valneva SE | -64.51 Million EUR | 92.139% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 82.111% |